(Q41268262)

English

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

scientific article published on 27 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 September 2017

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). (English)

1 reference

Europe PubMed Central

28 September 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Florian M Wagenlehner

1

1 reference

Europe PubMed Central

28 September 2017

Obiamiwe Umeh

2

1 reference

Europe PubMed Central

28 September 2017

Judith Steenbergen

3

1 reference

Europe PubMed Central

28 September 2017

Guojun Yuan

4

1 reference

Europe PubMed Central

28 September 2017

Rabih O Darouiche

5

1 reference

Europe PubMed Central

28 September 2017

language of work or name

0 references

publication date

27 April 2015

1 reference

Europe PubMed Central

28 September 2017

1 reference

Europe PubMed Central

28 September 2017

385

1 reference

Europe PubMed Central

28 September 2017

1949-1956

1 reference

Europe PubMed Central

28 September 2017

9981

1 reference

Europe PubMed Central

28 September 2017

Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic challenges of urosepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology, treatment and prevention of healthcare-associated urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimum risk weights for comparing treatments in stratified binomial trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing for interaction in studies of noninferiority.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Multistate point-prevalence survey of health care-associated infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Complicated urinary tract infection in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Levofloxacin for the treatment of pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ertapenem versus cefotetan prophylaxis in elective colorectal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962220-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)62220-0

1 reference

Europe PubMed Central

28 September 2017

1 reference

Europe PubMed Central

28 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41268262&oldid=2095761299"